[Management of monoclonal gammopathy]

The frequency of monoclonal gammopathy increases with age and heralds a (treatable) lymphoproliferative malignancy in approximately 20% of the patients. Follow-up of patients with monoclonal gammopathy is therefore of clinical relevance and may lead to new insights into the pathogenesis of lymphoproliferative malignancies. The recently developed guideline of the Dutch Institute for Health Care Improvement (CBO) serves both these goals.